Quantum Genomics to Participate in Biotech Showcase 2020

PARIS and NEW YORK, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC, OTCQX - QNNTF), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat resistant hypertension and heart failure, announces its participation in Biotech Showcase 2020 in San Francisco, being held on January 13-15, 2020, in parallel to the annual J.P. Morgan Healthcare Conference. 

On this occasion, Quantum Genomics Management team will present the latest developments of the company and will meet with both investors and pharmaceutical firms.

About Quantum Genomics

Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).

Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF).

For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedIn

Contact information                                                                                                                    

Quantum Genomics
Jean-Philippe MilonCEO+33 (0)1 85 34 77 70 | [email protected]	Marc KarakoCFO - Investor Relations+33 (0)1 85 34 77 70 | [email protected]
So Bang (Europe)
Nathalie BoumendilFinancial Communications +33 (0)6 85 82 41 95 | [email protected]	Samuel BeaupainMedia Relations and Scientific Communications+33 (0)6 88 48 48 02 | [email protected]
LifeSci (USA)
Dan FerryFinancial Communications +1 (617) 535-7746 | [email protected]	Mike TattoryMedia Relations and Scientific Communications+55 11 3573 6316 | [email protected]

 

Source: Quantum Genomics

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Bitget Upgrades Institutional Trading Framework to Power the Next Phase of Multi-Asset Markets
• GAK9, LED‑21, and La Sierra University Criminal Justice Department Launch Tactical K9 Training Hub in Southern California
• Oh My Ink Expands AI Tattoo Try-On Machines to the US, Its Third Market